Novavax Didn't Come Close to Analysts' Q3 Estimates -- and It's No Big Deal

It's been an absolutely fantastic year for Novavax (NASDAQ:NVAX); so far in 2020, the stock has skyrocketed more than 2,000%. Novavax belongs to an elite club of drugmakers with coronavirus vaccine candidates in late-stage testing.

Investors hoping for the year to get even better were eager to hear what Novavax had to say in its third-quarter update. Here are the biotech's numbers from Q3, and the bigger story behind those numbers.